Clinical trial

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

NCT04787744

Study summary

ClinicalTrials.gov

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

12 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

PROCEDURE · Unmapped registry intervention PET-directed Local Therapy using Surgery Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention PET-directed Local Therapy using Radiation Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Salvage Local Therapy for locally recurrent disease Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Goserelin, Histrelin, Leuprolide & Triptorelin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT + Nilutamide, Flutamide, & Bicalutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Degarelix & Relugolix Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT + Docetaxel +/- prednisone Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT + Abiraterone + Prednisone Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT + Abiraterone + Methylprednisolone Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT + Apalutamide Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention ADT + Enzalutamide Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Prostate-directed Radiation for De novo oligometastatic prostate cancer Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-07-01

PhasePHASE2 / PHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Oligometastasisunresolved

Oligorecurrenceunresolved

Recurrent Prostate Cancerunresolved

Metastatic Prostate Cancerverified · MONDO: metastatic prostate carcinoma

De Novo Prostate Cancerunresolved

Interventions

PET-directed Local Therapy using SurgeryPROCEDURE

PET-directed Local Therapy using RadiationRADIATION

Salvage Local Therapy for locally recurrent diseaseOTHER

Goserelin, Histrelin, Leuprolide & TriptorelinDRUG

ADT + Nilutamide, Flutamide, & BicalutamideDRUG

Degarelix & RelugolixDRUG

ADT + Docetaxel +/- prednisoneDRUG

ADT + Abiraterone + PrednisoneDRUG

ADT + Abiraterone + MethylprednisoloneDRUG

ADT + ApalutamideDRUG

ADT + EnzalutamideDRUG

Prostate-directed Radiation for De novo oligometastatic prostate cancerRADIATION

Sponsors & collaborators

VA Office of Research and Developmentlead sponsor

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 BostonMassachusetts, United States1 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 ClevelandOhio, United States1 DurhamNorth Carolina, United States1 Washington D.C.District of Columbia, United States1 IndianapolisIndiana, United States1 MinneapolisMinnesota, United States1 Ann ArborMichigan, United States1 RichmondVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04787744 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.